Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisatracurium 1 ED95 versus 2 ED95 for intraoperative neuromonitoring during thyroid surgery
ChiCTR1900022884Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cisatracurium in thyroid cancer (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Cooper score, Intubation Difficulty Scale score and 1 more. Started Oct 2019; status: recruiting.
02
Drugs
cisatracurium
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on ChiCTR1900022884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022884.